Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Radiopharmaceutical Theranostics Market Growth in 2025?

The market size of radiopharmaceutical theranostics has seen a significant expansion in the last few years. The expected progression is from $2.88 billion in 2024 to $3.27 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.7%. The historic period’s growth is due to factors such as developments in radiopharmaceuticals, advancements in clinical research, research investments, regulatory approvals, and progress in nuclear medicine.

What Is the Forecast for the Radiopharmaceutical Theranostics Market Size Through 2029?

Accelerated expansion is anticipated in the radiopharmaceutical theranostics market in the coming years. By the year 2029, the market is projected to reach $5.76 billion, growing at a compound annual growth rate (CAGR) of 15.2%. Factors contributing to this growth during the forecast period include discoveries and validation in biomarkers, advancements in genomic and proteomic technologies, development of precision radiotherapy, interdisciplinary collaborations, along with patient advocacy and support. The forecast period is also expected to see significant trends including ethical and legal factors, the incorporation of telemedicine in theranostics, patient-focused care, customization in radiopharmaceuticals, and the development of nano-theranostics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp

What are the Key Market Players in Radiopharmaceutical Theranostics Market and How They’re Evolving?

Major companies operating in the radiopharmaceutical theranostics market include Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

What Are the Primary Growth Drivers in the Radiopharmaceutical Theranostics Market?

The anticipated growth of the radiopharmaceutical theranostics market is due to the increasing occurrence of cancer. The disease, which is marked by a abnormal proliferation of cells spreading to other body parts, can be targeted and personalized through the use of radiopharmaceutical theranostics. For example, as projected by the American Cancer Society in 2023, the United States may see an estimated 1.9 million new cases of cancer, with around 609,820 resulting fatalities. Furthermore, it is expected that 88% of these diagnoses will be in people aged 50 and over. Consequently, the upsurge in cancer instances is a key driver for the expansion of the radiopharmaceutical theranostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11951&type=smp

What Are the Leading Segments in the Global Radiopharmaceutical Theranostics Industry?

The radiopharmaceutical theranostics market covered in this report is segmented –

1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers

2) By Source: Nuclear Reactors, Cyclotrons

3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes

4) By Indication: Oncology, Cardiology, Neurology, Other Indications

5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals

2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals

3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET Tracers

What Are the Key Market Trends in the Radiopharmaceutical Theranostics Industry?

In the radiopharmaceutical theranostics market, primary businesses are embracing strategies of partnership to cultivate innovative treatments. These collaborations offer numerous benefits such as pooling resources and knowledge, bolstering research and development capabilities, broadening market penetration, and speeding up commercialization, all of which contribute to fueling innovation and expansion within the industry. For example, in March 2023, the biotech firm in Australia, Radiopharm Theranostics formed a collaboration with the U.S.-based Pharma15 Corporation. Their combined efforts are concentrated on creating a new generation of therapeutic radiopharmaceuticals that are aimed at prostate cancer and particularly committed to overcoming the obstacles to current PSMA-targeted treatments, while also increasing selectivity to reduce damage to healthy tissues.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

What Is the Regional Outlook for the Radiopharmaceutical Theranostics Market?

North America was the largest region in the radiopharmaceutical theranostics market in 2024. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11951

This Report Delivers Insight On:

1. How big is the radiopharmaceutical theranostics market, and how is it changing globally?

2. Who are the major companies in the radiopharmaceutical theranostics market, and how are they performing?

3. What are the key opportunities and risks in the radiopharmaceutical theranostics market right now?

4. Which products or customer segments are growing the most in the radiopharmaceutical theranostics market?

5. What factors are helping or slowing down the growth of the radiopharmaceutical theranostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model